Pfizer said on Tuesday its cancer drug Padcev, in combination with Merck's Keytruda, significantly improved survival rates in ...

Pfizer, Inc. (PFE) stock is incredibly cheap following management's raise of its 2025 adjusted earnings per share guidance.

Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...

Chief Executive Albert Bourla says he is hopeful about finding a solution in response to Trump’s demand for price cuts.

Shares in the data-software company were up 7.8% Tuesday after it posted higher quarterly results and [boosted its annual ...

The rising bladder cancer star that is the combination of Pfizer and Astellas’ Padcev and Merck’s Keytruda is looking to set ...

Those who invested in Pfizer three years ago and hung on are not thrilled. They would have done much better with a simple S&P ...

How Do Unusual Items Influence Profit? For anyone who wants to understand Pfizer's profit beyond the statutory numbers, it's ...

Pfizer (PFE) stock is in focus as the company and Astellas (ALPMF) post a late-stage trial win for their cancer drug Padcev ...

Pfizer said its antibody-drug conjugate Padcev extended survival when combined with the immunotherapy Keytruda in some ...